https://www.selleckchem.com/pr....oducts/1-azakenpaull
The sensitivity and specificity of circRNAs in distinguishing BC patients from noncancerous controls were 0.65 and 0.68, and the corresponding area under the curve was 0.66. Survival analysis revealed that patients showing highly expressed oncogenic circRNAs were associated with increased mortality risks of BC in overall survival (univariate analysis hazard ratio [HR]=3.30, P=.000; multivariate analysis HR=3.07, P=.00, and disease-free survival (HR=8.26, P=.00. Stratified analysis based on circRNA expression status and cont